SPOT-MAS operates through blood analysis and detects signs of several aggressive cancer types using a single blood sample. It embraces DNA sequencing, as well as analysis of methylation and fragmentation, to detect likely cancer signals based on the projected tissue of origin. Clinical verification and actual deployment in Asia exhibit high specificity (usually above 95 per cent) but rising sensitivity in detecting cancer based on several cancer biomarkers.